SEOUL -- After successfully penetrating the European market, South Korean pharmaceutical company Celltrion has set its sights on a new target: China.
Celltrion is poised to break into the Chinese market as early as 2020 via a joint venture that will allow it to sell biopharmaceuticals in the world's most-populous market.
